In this study, we examined the safety and immunogenicity, including the mucosal secretory IgA response, of the combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old. The gene discussed is CD79A; the disease is COVID-19.